Roger Bullock
Kingshill Research Centre
Swindon
UK
[email]@kingshill-research.org
Name/email consistency: high
- Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Bullock, R., Lane, R. Curr. Alzheimer. Res (2007)
- Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock, R., Bergman, H., Touchon, J., Gambina, G., He, Y., Nagel, J., Lane, R. Curr. Med. Res. Opin (2006)
- SGS-742 Novartis. Bullock, R. Curr. Opin. Investig. Drugs (2005)
- Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Bullock, R. Curr. Med. Res. Opin (2005)
- Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Bullock, R., Dengiz, A. Int. J. Clin. Pract. (2005)
- Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., Lane, R. Curr. Med. Res. Opin (2005)
- Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Bullock, R., Erkinjuntti, T., Lilienfeld, S. Dement. Geriatr. Cogn. Disord (2004)
- Cholinesterase inhibitors and vascular dementia: another string to their bow?. Bullock, R. CNS. Drugs (2004)
- Future directions in the treatment of Alzheimer's disease. Bullock, R. Expert. Opin. Investig. Drugs (2004)
- The needs of the caregiver in the long-term treatment of Alzheimer disease. Bullock, R. Alzheimer. Dis. Assoc. Disord (2004)
- Galantamine: use in Alzheimer's disease and related disorders. Bullock, R. Expert. Rev. Neurother (2004)
- Realistic expectations: the management of severe Alzheimer disease. Bullock, R., Hammond, G. Alzheimer. Dis. Assoc. Disord (2003)
- New drugs for Alzheimer's disease and other dementias. Bullock, R. Br. J. Psychiatry (2002)
- Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?. Bullock, R., Connolly, C. Int. J. Geriatr. Psychiatry (2002)
- Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Bullock, R., Cameron, A. Curr. Med. Res. Opin (2002)